Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share allocation details rather than financial performance metrics.
Material Changes
The filing details the acquisition of Ordinary Shares by specific Directors and PDMRs following the re-investment of the dividend paid on October 1, 2015. The shares were acquired at a price of 1,294.81 pence per Share. GSK was informed of these allocations on October 16, 2015.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of director shareholdings.
Important Facts for Investors
- Transaction Type: Share acquisitions via dividend re-investment plan.
- Share Price: 1,294.81 pence per Share.
- Key Participants: Includes Sir Andrew Witty, Mr. S A Hussain, Dr. P J T Vallance, and others.
- Notification Date: GSK was informed of allocations on October 16, 2015.
- Reporting Limitation: This filing contains no financial performance data or strategic outlook.